Global Oscillating Positive Expiratory Pressure (OPEP) Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Oscillating Positive Expiratory Pressure (OPEP) Market Size

• The global oscillating positive expiratory pressure (OPEP) market size was valued at USD 2.67 billion in 2024 and is expected to reach USD 4.20 billion by 2032, at a CAGR of 5.80% during the forecast period
• The market growth is largely driven by the increasing prevalence of chronic respiratory diseases such as COPD, cystic fibrosis, and asthma, alongside the rising demand for non-invasive, user-friendly pulmonary therapy devices
• Furthermore, growing awareness about respiratory health and advancements in portable, home-use OPEP devices are enhancing patient compliance and adoption. These factors are collectively propelling the market forward, positioning OPEP devices as a key component in modern respiratory therapy strategies

Oscillating Positive Expiratory Pressure (OPEP) Market Analysis

• Oscillating positive expiratory pressure (OPEP) devices, used for airway clearance therapy, are becoming essential in managing chronic respiratory conditions by helping patients mobilize and expel mucus, thereby improving lung function and reducing infections in both homecare and clinical settings
• The rising demand for OPEP devices is primarily driven by the increasing prevalence of respiratory disorders such as COPD, asthma, and cystic fibrosis, along with a growing preference for non-invasive, portable, and patient-friendly treatment options
• North America dominated the oscillating positive expiratory pressure (OPEP) market with the largest revenue share of 40.5% in 2024, characterized by high disease awareness, advanced healthcare infrastructure, and supportive reimbursement policies, especially in the U.S., where home respiratory therapy is seeing increased adoption amid a shift toward patient-centric care
• Asia-Pacific is expected to be the fastest growing region in the oscillating positive expiratory pressure (OPEP) market during the forecast period due to rising burden of respiratory diseases, growing elderly population, and increased healthcare investments
• Facemask OPEP Devices segment dominated the oscillating positive expiratory pressure (OPEP) market with a market share of 50.5% in 2024, driven by its superior patient comfort, ease of use, and suitability for a wide range of age groups and respiratory conditions

Report Scope and Oscillating Positive Expiratory Pressure (OPEP) Market Segmentation     

Oscillating Positive Expiratory Pressure (OPEP) Market Trends

“Technological Advancements in Portable and Digital OPEP Devices”

• A significant and accelerating trend in the global OPEP market is the development of portable and digitally integrated devices that enhance accessibility, ease of use, and therapy adherence for patients managing chronic respiratory conditions in both homecare and clinical environments
  • For instance, the Aerobika OPEP device is widely adopted for its compact design and ease of operation, enabling patients to perform effective airway clearance therapy independently. Similarly, the Acapella Choice combines PEP therapy with airway vibrations to enhance mucus clearance with minimal effort
• Digital integration in OPEP devices is enabling features such as real-time usage monitoring, session tracking, and app connectivity, allowing healthcare providers to tailor treatments and improve long-term outcomes. Some advanced models now sync with mobile platforms to provide feedback, reminders, and progress reports
• The ability to monitor therapy compliance remotely supports the growing emphasis on telehealth and decentralized care, offering both patients and clinicians greater control and flexibility. This is especially valuable for elderly or mobility-limited users requiring long-term respiratory support
• These smart and portable devices are also benefiting from improved ergonomic designs, antimicrobial materials, and noise reduction technologies, enhancing patient comfort and hygiene. Manufacturers such as Monaghan Medical and PARI Respiratory are leading this innovation wave, focusing on integrating digital features into traditional OPEP systems
• This trend towards compact, connected, and intelligent respiratory therapy devices is transforming the delivery of pulmonary care, with increasing adoption across global markets as patients and healthcare systems prioritize non-invasive, home-based treatment solutions

Oscillating Positive Expiratory Pressure (OPEP) Market Dynamics

Driver

“Rising Prevalence of Chronic Respiratory Diseases and Demand for Home-Based Therapy”

• The increasing global burden of chronic respiratory conditions such as COPD, asthma, and cystic fibrosis is a major driver for the growing demand for oscillating positive expiratory pressure (OPEP) devices, particularly as healthcare systems shift focus toward non-invasive, self-managed treatment solutions
  • For instance, in March 2024, Monaghan Medical Corporation expanded its line of OPEP devices with the launch of a portable unit designed for personalized airway clearance therapy, supporting at-home care for chronic respiratory patients. Such product innovations are expected to significantly propel market growth
• As patient awareness of respiratory health improves and the preference for effective, user-friendly devices rises, OPEP systems offer benefits such as mucus clearance, improved lung function, and reduced infection risks—making them an essential component of long-term respiratory management
• Furthermore, the increasing demand for home-based healthcare, particularly among the elderly and post-acute care patients, is enhancing the adoption of compact, portable OPEP devices that can be used independently with minimal supervision
• Technological advancements, improved ergonomics, and integration with digital health tools are also enabling better compliance and remote monitoring, which align with the global trend toward patient-centric and cost-effective respiratory care outside traditional clinical settings.

Restraint/Challenge

“Skin Irritation Issues and Regulatory Compliance Hurdle”

• Skin irritation and discomfort associated with prolonged or improper use of facemask-based OPEP devices represent a notable restraint, especially for pediatric and elderly patients with sensitive skin. These issues can lead to reduced compliance, limiting the effectiveness of therapy over time
  • For instance, reports of facial redness or pressure-related discomfort with certain mask interfaces have led clinicians and users to favor alternate devices or require modifications in usage protocols, impacting overall adoption
• In addition, the stringent regulatory requirements for medical device approvals—especially in regions such as the U.S. (FDA) and EU (CE marking)—can slow down product introductions and increase development costs. OPEP device manufacturers must navigate complex clinical testing, documentation, and safety verification processes to meet compliance standards
• These regulatory challenges may particularly hinder smaller or emerging manufacturers seeking to enter global markets, where the cost and time required for certifications may delay commercialization
• To overcome these restraints, companies are focusing on improving device ergonomics, offering hypoallergenic materials, and streamlining product development to align with evolving regulatory frameworks. Investments in clinical validation and patient-centric design will be essential for broader market acceptance and sustainable growth

Oscillating Positive Expiratory Pressure (OPEP) Market Scope

The market is segmented on the basis of product type, indication, and distribution channel.

• By Product Type

On the basis of product type, the oscillating positive expiratory pressure (OPEP) market is segmented into facemask OPEP devices, mouthpiece OPEP devices, and bottle OPEP devices. The facemask OPEP devices segment dominated the market with the largest market revenue share of 50.5% in 2024, driven by its high usage among pediatric and elderly patients who often face challenges using mouthpiece-based devices. These facemasks offer better sealing, comfort, and ease of use during therapy, especially in non-compliant or physically impaired individuals. Healthcare providers also favor facemask OPEP devices in clinical settings due to their adaptability and broad patient compatibility.

The mouthpiece OPEP devices segment is anticipated to witness the fastest growth rate from 2025 to 2032, owing to increased homecare adoption and portability advantages. These devices are compact, reusable, and preferred for their ease of cleaning and suitability for independent usage in chronic respiratory conditions such as COPD and asthma. The trend toward self-managed care and outpatient respiratory therapy continues to boost demand for mouthpiece-based models globally.

• By Indication

On the basis of indication, the oscillating positive expiratory pressure (OPEP) market is segmented into COPD, asthma, atelectasis, bronchitis, bronchiectasis, cystic fibrosis, and others. The COPD segment held the largest revenue share in 2024, driven by the rising global prevalence of chronic obstructive pulmonary disease and its strong clinical alignment with OPEP therapy for mucus clearance and lung expansion. With increasing disease burden among the aging population and smokers, COPD remains the primary target for OPEP interventions across hospital and homecare settings.

The cystic fibrosis segment is projected to grow at the fastest CAGR through 2032, especially in developed markets such as North America and Europe, where early screening and lifelong respiratory therapy are standard. OPEP devices play a critical role in airway clearance regimens for cystic fibrosis patients, offering a non-invasive, effective therapy that improves long-term pulmonary outcomes.

• By Distribution Channel

On the basis of distribution channel, the oscillating positive expiratory pressure (OPEP) market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies/online sales. Hospital pharmacies dominated the segment in 2024 due to higher demand from inpatient and outpatient clinical settings for both acute and chronic respiratory management. Hospitals typically procure bulk OPEP devices for rehabilitation units, especially in post-operative and respiratory care.

Online pharmacies/online sales are expected to register the fastest growth from 2025 to 2032, fueled by the increasing popularity of e-commerce platforms, direct-to-consumer models, and improved patient accessibility to respiratory care products at home. The convenience of home delivery, better price transparency, and access to product comparisons are driving growth in this channel, particularly among chronic care users seeking home-based therapy solutions.

Oscillating Positive Expiratory Pressure (OPEP) Market Regional Analysis

• North America dominated the oscillating positive expiratory pressure (OPEP) market with the largest revenue share of 40.5% in 2024, driven by high disease awareness, advanced healthcare infrastructure, and supportive reimbursement policies
• Patients and healthcare providers in the region increasingly prefer OPEP devices due to their non-invasive nature, proven clinical efficacy, and ease of use in both hospital and homecare settings. Growing awareness about respiratory health and advancements in device technology also contribute to market growth
• The region's leadership is further supported by significant investments in respiratory care research, presence of leading OPEP device manufacturers, and expanding adoption in outpatient pulmonary rehabilitation programs, making North America a key market for OPEP devices globally

U.S. Oscillating Positive Expiratory Pressure (OPEP) Market Insight

The U.S. oscillating positive expiratory pressure (OPEP) market captured the largest revenue share of 82% in 2024 within North America, driven by the high prevalence of chronic respiratory conditions such as COPD and cystic fibrosis. The increasing adoption of home-based respiratory therapies and pulmonary rehabilitation programs, coupled with rising awareness about non-invasive treatment options, is propelling market growth. Furthermore, robust healthcare infrastructure and reimbursement policies supporting OPEP device usage significantly contribute to the market’s expansion.

Europe Oscillating Positive Expiratory Pressure (OPEP) Market Insight

The Europe oscillating positive expiratory pressure (OPEP) market is projected to grow at a steady CAGR throughout the forecast period, primarily driven by increasing cases of respiratory diseases and stringent healthcare regulations promoting advanced respiratory care. Rising investments in healthcare infrastructure and the growing preference for non-invasive pulmonary therapy devices in hospitals and homecare settings are boosting adoption. Countries such as Germany and the U.K. show considerable demand for OPEP devices, supported by strong healthcare funding and patient awareness initiatives.

U.K. Oscillating Positive Expiratory Pressure (OPEP) Market Insight

The U.K. oscillating positive expiratory pressure (OPEP) market is expected to grow at a notable CAGR during the forecast period, fueled by the rising incidence of respiratory disorders and an increasing focus on pulmonary rehabilitation. Government programs encouraging the use of cost-effective and non-invasive respiratory aids, alongside a well-established healthcare system, are encouraging adoption in both clinical and homecare environments. The demand for easy-to-use OPEP devices is also rising among elderly patients and those with chronic lung conditions.

Germany Oscillating Positive Expiratory Pressure (OPEP) Market Insight

The Germany’s oscillating positive expiratory pressure (OPEP) market is anticipated to expand at a significant CAGR during the forecast period, supported by the country’s advanced healthcare system and technological innovation in medical devices. Increased awareness regarding respiratory health, coupled with government initiatives for chronic disease management, is driving the uptake of OPEP devices. Germany’s emphasis on preventive healthcare and growing adoption of pulmonary rehabilitation programs contribute to steady market growth.

Asia-Pacific Oscillating Positive Expiratory Pressure (OPEP) Market Insight

The Asia-Pacific oscillating positive expiratory pressure (OPEP) market is poised to register the fastest CAGR from 2025 to 2032, driven by a growing patient population with respiratory diseases and increasing healthcare expenditure in countries such as China, India, and Japan. Rising urbanization, expanding healthcare infrastructure, and growing awareness about respiratory therapy options are key factors accelerating adoption. In addition, increased manufacturing capabilities and government support for affordable medical devices are enhancing market penetration.

Japan Oscillating Positive Expiratory Pressure (OPEP) Market Insight

The Japan’s oscillating positive expiratory pressure (OPEP) market is gaining traction due to the country’s aging population and high incidence of chronic respiratory diseases. The growing emphasis on improving patient quality of life through home-based therapies and integration of advanced medical technologies are driving demand. Furthermore, Japan’s strong medical device industry supports innovation and adoption of user-friendly OPEP devices, especially in elderly care and rehabilitation sectors.

India Oscillating Positive Expiratory Pressure (OPEP) Market Insight

The India oscillating positive expiratory pressure (OPEP) accounted for the largest market revenue share in Asia-Pacific in 2024, attributed to the rising burden of respiratory illnesses, increasing healthcare awareness, and expanding healthcare infrastructure. The government’s focus on improving access to respiratory care and affordable medical devices is driving the market. In addition, the availability of cost-effective OPEP devices through domestic manufacturers and increasing penetration in both urban and rural healthcare facilities support sustained growth.

Oscillating Positive Expiratory Pressure (OPEP) Market Share

The oscillating positive expiratory pressure (OPEP) industry is primarily led by well-established companies, including:

• Trudell Medical International (Canada)
• Hill-Rom Holdings, Inc. (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• Smiths Group plc (U.K.)
• Teleflex Incorporated (U.S.)
• ResMed Inc. (U.S.)
• BD (U.S.)
• Medtronic (Ireland)
• PARI GmbH (Germany)
• InspiRx, Inc. (U.S.)
• Vyaire Medical, Inc. (U.S.)
• HMC Respiratory Devices (China)
• Omron Healthcare, Inc. (Japan)
• Medical Depot, Inc. (U.S.)
• Nihon Kohden Corporation (Japan)
• Fisher & Paykel Healthcare (New Zealand)
• Allied Healthcare Products, Inc. (U.S.)

What are the Recent Developments in Global Oscillating Positive Expiratory Pressure (OPEP) Market?

• In April 2024, A study published in the European Respiratory Journal assessed the effectiveness of various OPEP devices, including the Acapella device, in facilitating mucus clearance in patients with chronic respiratory conditions. The findings support the clinical efficacy of OPEP therapy in improving pulmonary function and reducing exacerbations
• In April 2024, Trudell Medical International (TMI) conducted a study evaluating the medication delivery performance of hypertonic saline administered via a nebulizer with breath-actuated technology (inhalation) attached to an OPEP device (exhalation). This combination system demonstrated improved aerosol delivery efficiency, suggesting enhanced treatment outcomes for respiratory conditions
• In February 2024, a clinical study in Wales, UK, assessed the effectiveness of a handheld OPEP device in patients with Chronic Obstructive Pulmonary Disease (COPD) experiencing mucus hypersecretion after exacerbation. The study compared the OPEP device’s performance with the Active Cycle of Breathing Techniques (ACBT), providing important insights into clinical management of COPD symptoms
• In January 2024, Trudell Medical International published a laboratory investigation comparing four different OPEP devices, analyzing total pressure pulse impact (TPPI) and other performance metrics. The study aimed to guide clinicians in selecting the most effective OPEP device for respiratory therapy
• In January 2024, Trudell Medical International released a comprehensive study on the Aerobika Oscillating Positive Expiratory Pressure (OPEP) device, highlighting its effectiveness in improving lung function and quality of life for patients with chronic respiratory conditions. The study underscores the device's role in airway clearance therapy, offering a drug-free solution for managing diseases such as COPD and cystic fibrosis

SKU-50290